A single-center experience in combined oncological–surgical treatment for resectable locally advanced non-small cell lung cancer (nsclc)

HIGHLIGHTS

• What: This approach showed a mere increase in the overall survival rate by 5% upon the administration of platinum-based chemotherapy of cisplatin or carboplatin . This study retrospectively evaluated all aspects of Carmel Medical Center experience with this complex group of patients with lung cancer, i.e., stage III NSCLC. This study focus is on surgical patients who represent a very unique and small subgroup of the heterogenic stage III lung cancer population. The aim was to revise the path taken along the treatment plan offered to the patients.
• Who: Dan Levy Faber and collaborators . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.